<DOC>
	<DOCNO>NCT00446264</DOCNO>
	<brief_summary>The restoration endogenous insulin secretion carry significant hope shift paradigm life long exogenous insulin therapy select group patient type 1 diabetes ( T1D ) . After decade frustrate clinical attempt , Edmonton group set 2000 new standard islet transplantation patient brittle T1D achieve insulin independence 80 percent patient . These seminal result however prove much difficult duplicate initially expect . This single center phase 2 clinical trial , duplicate Edmonton protocol , design confirm consistent short term efficacy safety sequential islet allotransplantation steroid free immunosuppression patient severe T1D .</brief_summary>
	<brief_title>Islet Allotransplantation With Steroid Free Immunosuppression</brief_title>
	<detailed_description>The short term effectiveness islet transplantation alleviate hypoglycemia control glucose homeostasis limit even avoid nedd exogenous insulin establish despite protocol modification donor selection , islet preparation recipient treatment , insulin independence adequate metabolic control however rarely prolonged beyond two year . The frequently propose explanation include chronic allogenic rejection , recurrence autoimmunity beta cell toxicity administer immunosuppressive drug . Fourteen patient enrol single center phase 2 trial initiated 2003 . Eligible patient male female 18 65 year age , type 1 diabeted document 5 year , arginine stimulate C-peptide low 0.2ng/ml , hypoglycemia awareness document metabolic lability . Exclusion criterion include body mass index great 28Kg/m2 , unstable arteriopathy heart disease , active infection , previous transplantation , insulin daily requirement 1.2 UI/kg , creatinin clearance 60 ml/mn/m2 urinary albumin excretion 300 mg/day , malignancy , smoking , desire pregnancy , psychiatric disorder lack compliance . The study primary efficacy endpoint graft survival define insulin independence HbA1c &lt; 6.5 % . Secondary outcome graft function metabolic control .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>type 1 diabetes document 5 year arginine stimulate Cpeptide low 0.2 ng/mL one following : hypoglycemia unawareness OR metabolic lability document one severe hypoglycemia two hospital admission ketoacidosis within previous year . body mass index great 28 kg/m2 non stable arteriopathy heart disease active infection previous transplantation hyperimmunization insulin daily need 1.2 U/Kg creatinine clearance 60 ml/mn urinary albumin excretion 300 mg/d malignancy smoke desire pregnancy psychiatric disorder lack compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>diabetes</keyword>
	<keyword>hypoglycemia</keyword>
</DOC>